For individuals with kidney disease, especially those with severe impairment (e.g., chronic kidney disease stage 4 or 5), careful consideration is necessary before prescribing Avana. Studies have indicated that patients with moderate to severe renal impairment may require dosage adjustments to avoid potential complications. The accumulation of Avana in the body due to reduced kidney function could exacerbate side effects and compromise safety. Research focused on Avana use in patients with varying degrees of kidney disease has highlighted the importance of tailored dosing regimens. Clinical trials have demonstrated that while Avana may still be effective in these populations, adjustments based on renal function are crucial to minimize risks and optimize therapeutic outcomes.